In this issue:
Prognostic value of HER2 status
The incidence of MBC within 5 years post non-MBC diagnosis
PABC as a prognostic feature GEP test adoption
Decline in anthracycline use
Clinical relevance of CTCs
Review of sequential endocrine therapies
Trastuzumab retreatm
Please login below to download this issue (PDF)